Top member reports
No meetings
Consensus community valuation
XXXXXX
Average Intrinsic Value
XXXXXX
Undervalued by
The consensus valuation is for members only and has been removed from this chart. Click for membership options.
Contributing Members
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
Valuation of $5.10
Added a month ago

I participated in the IPO and have followed CCL closely since listing. The 1H26 result confirms the business is settling into its listed life and starting to show its operating leverage. Underlying NPAT grew 13%, NOI was up 10%, and transaction volumes lifted 9% across all core capabilities. It’s steady, repeatable growth from a regulated payments operator with real barriers to entry.

The Indue acquisition is the swing factor. One month of ownership added $5.3m of NOI, and management reaffirmed $15–20m post‑tax annual synergies by FY29. If they deliver even the midpoint, the earnings base steps up meaningfully.

On valuation, the market is still treating CCL like a low‑growth processor. I think it’s roughly 30% undervalued, with a fair value around $5.10 based on mid‑teens NPAT growth and the synergy runway.

This is a quiet compounder. I’m holding for the multi‑year rerate.

Read More
#Financials
Added a month ago

Cuscal (CCL) — 1H26 Result & Forward Value

I participated in the IPO and have followed CCL closely since listing. The 1H26 result confirms what I backed at float: this is a defensive, transaction‑driven operator with genuine operating leverage now starting to show through.

The core of the story:

CCL is one of only five entities in Australia with full payments‑rail connectivity (the four majors + Cuscal). That regulatory moat is real, expensive to replicate, and getting stronger as compliance, cyber, and fraud‑monitoring costs rise across the sector. Their B2B model means they don’t compete with their own customers, and the client base is long‑tenured, contracted, and volume‑linked.

1H26 showed three things clearly:

Underlying NPAT +13% — the business is scaling again after the heavy FY22–FY25 investment cycle.

Transaction volumes +9% — broad‑based strength across issuing, acquiring, and payments.

Indue acquisition is already accretive — $5.3m NOI contribution in one month, with $15–20m post‑tax synergies reaffirmed.

Why it matters:

This is a classic “earnings compounder hiding inside a regulated utility.” Once Indue is fully integrated (FY29), the combined entity should be structurally more profitable, more diversified, and more resilient. The synergy targets are large relative to the current earnings base, and management has a track record of disciplined execution.

Forward value:

If CCL delivers mid‑teens underlying NPAT growth (as guided), maintains its capital strength, and realises even the midpoint of Indue synergies, the earnings profile in FY28–FY30 looks meaningfully higher than today. The market is still pricing CCL like a slow‑moving payments processor; the trajectory now looks more like a scaled infrastructure provider with operating leverage ahead of it.

Disclosure: I’m holding for that multi‑year rerate.

Read More
#b2bsoftwarebunny
stale
Added 9 months ago

I seek the code where margins gleam,

To clip the ticket is my dream.

But giants stalk the minnow's field,

Their market power might make us yield.

Read More
#Investment Thesis
stale
Added 10 months ago

I'm not holding this one, but came across this today:

https://arichlife.com.au/potential-hidden-small-cap-gem-still-flying-under-the-radar/ [10-April-2025]

by Claude Walker @ A Rich Life. Now no longer behind a paywall.

Not my type of company personally, I tend to shy away from fintechs and biotechs, and this seems to be a fintech, even if it's not really any new tech, just old tech done well by the looks of it. More a backroom payments system company. But a trusted one (not like ISX, a.k.a. Southern Cross Payments).

Read More